Gene Therapy
The Latest
-
BioMarin Pharmaceuticals' Stock Price Falls After FDA Rejects Treatment Application
BioMarin Pharmaceuticals' shares fell more than 31 percent Wednesday after the FDA called for more data about its hemophilia therapy. 
BioMarin Pharmaceuticals' shares fell more than 31 percent Wednesday after the FDA called for more data about its hemophilia therapy. -
Drugmakers Investing Billions In Building Internal Gene Therapy Facilities
Since 2018, major drugmakers have invested a combined $2 billion in establishing their own gene therapy manufacturing facilities. 
Since 2018, major drugmakers have invested a combined $2 billion in establishing their own gene therapy manufacturing facilities. -
FDA Approves World's Most Expensive Drug Priced At $2.1 Million
Novartis' Zolgensma drug is a one-time gene therapy treatment for people suffering from spinal muscular atrophy. 
Novartis' Zolgensma drug is a one-time gene therapy treatment for people suffering from spinal muscular atrophy.
